Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance

An early molecular response is spectacularly predictive of outcome in chronic myeloid leukemia (CML) and early response landmarks may identify the high-risk patients likely to be benefit from an early therapy switch. In this study, we evaluated the most relevant cutoffs for early molecular response...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Blood Cancer J
Hoofdauteurs: Zhang, Jingru, Wang, Yingqiao, Wang, Jianxiang, Hu, Jianda, Chen, Suning, Jin, Jie, Liu, Ting, Zhou, Jianfeng, Hu, Yu, Ma, Daoxin, Huang, Xiaojun, Ji, Chunyan, Hou, Ming
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Nature Publishing Group UK 2018
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6006175/
https://ncbi.nlm.nih.gov/pubmed/29915172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-018-0093-4
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items